In recent years, a number of immune checkpoint inhibitors have been granted FDA approval. Although efficient, monoclonal antibodies targeting immune checkpoints have been found to produce objective and durable anti-tumor response in a limited number of cancer patients. To identify novel therapeutic strategies capable of enhancing the efficacy of immune checkpoint inhibitors, Porsolt offers validated syngeneic mouse tumor model of anti-CTLA-4 and anti-PD-L1 immunotherapies.
PREDICTIVE IN VIVO MODELS OF ANTI-CTLA-4 & ANTI-PD-L1 CANCER IMMUNOTHERAPIES
- Syngeneic tumor models: to closely recapitulate tumor-immune system interactions, tumor cells are inoculated into immunocompetent mice.
- A well-characterized colorectal cancer model of immune checkpoint blockade, which responds to CTLA-4 inhibition but not to anti-PD-L1 immunotherapy
ASSESSMENT OF ANTI-TUMOR EFFICACY AND IMMUNE RESPONSE PROFILE
- Preclinical efficacy study: Experimental groups (N=8-10) are monitored 3 times per week. Readouts include tumor size, survival and body weight.
- Immune response assessment: satellite mice are added to each group for immune profiling at the tumor site or in peripheral compartments (spleen, lymph nodes) by flow cytometry or high-content imaging.
- Fast study initiation and weekly reports: syngeneic tumor models are set up and ready for treatment within 15 to 20 days after proposal validation. Preliminary reports are then are communicated every week.
- Validated markers of immune response: CD4, CD8, CD25, FOXP3, CD11b, Gr1, CD11c, mPDCA1...
- RTq-PCR analysis for immune-related genes: Il6, Ifng, Il17, Tnfa, Tgfb, Il10, Foxp3, Rorgt, Cd274 (PD-L1), Pdcd1 (PD1), …